Clinical Trials
43 trialsMK-3475-G21
Merck Sharp & Dohme LLC
MK-3475-051
Merck Sharp & Dohme LLC
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
PRIMAVERA
AstraZeneca
KEYNOTE145
Acerta Pharma BV
MK-3475-667
Merck Sharp & Dohme LLC
MK-3475-204
Merck Sharp & Dohme LLC
MK-3475-D20
BioInvent International AB
MK-4280-003
Merck Sharp & Dohme LLC
MK-4280A-008
Merck Sharp & Dohme LLC
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
MK-1454-001
Merck Sharp & Dohme LLC
MK-3475-B68
Merck Sharp & Dohme LLC
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
MK-2118-001
Merck Sharp & Dohme LLC
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
KEYNOTE-A33
Merck Sharp & Dohme LLC
Meteor 1
GlaxoSmithKline
IT-01
Intensity Therapeutics, Inc.
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
Merus B.V.
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Merck Sharp & Dohme LLC
HARBOUR
Amgen
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Glenmark Specialty S.A.
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
I-Mab Biopharma US Limited
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
NEON-2
Alpine Immune Sciences, Inc.
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Phase 1 First-in-human Study of JS014
Anwita Biosciences
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
VITALIZE
ImmunoVaccine Technologies, Inc. (IMV Inc.)
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Repertoire Immune Medicines
PORTIA
Novartis
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
MK-3475-013
Merck Sharp & Dohme LLC
KEYNOTE-155
Merck Sharp & Dohme LLC
MK-3475-174
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Rhizen Pharmaceuticals SA
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Affimed GmbH
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS